Monday, June 30, 2025 6/30/2025

Elucidating the mechanism of ERbeta in colon carcinogenesis

Award Number: R01CA172437
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2013
PERIOD OF PERFORMANCE END DATE: 03/31/2019

Group Awards By:

View Award Description

Elucidating the mechanism of ERbeta in colon carcinogenesis - DESCRIPTION (provided by applicant): A truly preventive or targeted therapy against colon cancer does not yet exist. However, hormone replacement therapy in women unexpectedly resulted in reduced risk of colorectal cancer, use of oral contraceptives is associated with a lower incidence of this disease, and estradiol has been shown to reduce the formation of preneoplastic lesions in the colon. Estrogen receptor beta (ERß) is the predominant estrogen receptor in the human colonic epithelium; polymorphisms in this gene are related to colon cancer incidence and its loss in tumors is related to advanced Dukes staging and poorer survival. In vivo mouse studies have demonstrated that ERß agonist treatment prevents intestinal tumor development and that deletion of ERß leads to an increase in colon adenomas. Collectively, these observations clearly point to a protective role for ERß in colorectal cancer. Estrogen receptors have significant consequences in health and diseases. They can be activated or inactivated by ligands, and are ideal candidates for therapeutic targeting. Compounds exist that selectively activate ERß, circumventing the adverse effects that estrogen induces in men and women through ERα activation. As ERß hold significant potential as a target for colon cancer therapy, it is essential to understand the basic mechanistic background of its action and to identify biomarkers of its activity. The PI's preliminary data supports the existence of three critical mechanisms whereby ERß exerts these effects in the colon. These three mechanisms are 1) a predicted ERß and PROX1 interaction, 2) an anti-inflammatory response via repression of NFkB/IL-6 signaling and 3) anti-oncogenic effects through the regulation of miRNA mediated pathways, including the miR17-92 and miR-200a/b clusters. This project takes advantage of the skills of the Center for Nuclear Receptors and Cell Signaling to provide a detailed understanding of ERß's role and potential in colon cancer prevention and treatment. The overall objective of this project is to provide the mechanistic basis for novel colo cancer prevention and therapy utilizing ERß.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2020 ( Subtotal = $0 )
2020	2018	KAROLINSKA INST	NOBELS VAG 6	SOLNA	STOCKHOLM	171 65		SWE	Cancer Biology Research	000	6	1/3/2020	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2018 ( Subtotal = $224,100 )
2018	2018	KAROLINSKA INST	SOLNAVAGEN 1	SOLNA		17165		SWE	Cancer Biology Research	000	6	3/28/2018	NON-COMPETING CONTINUATION	$201,690
2018	2018	KAROLINSKA INST	SOLNAVAGEN 1	SOLNA		17165		SWE	Cancer Biology Research	001	6	5/24/2018	NON-COMPETING CONTINUATION	$22,410
														Subtotal = $224,100

Issue Date FY: 2017 ( Subtotal = $224,100 )
2017	2017	KAROLINSKA INST	NOBELS VAG 5	SOLNA		17165		SWE	Cancer Biology Research	001	5	6/12/2017	NON-COMPETING CONTINUATION	$22,410
2017	2017	KAROLINSKA INST	NOBELS VAG 5	SOLNA		17165		SWE	Cancer Biology Research	000	5	4/13/2017	NON-COMPETING CONTINUATION	$201,690
														Subtotal = $224,100

Issue Date FY: 2016 ( Subtotal = $0 )
2016	2015	KAROLINSKA INSTITUTE, RYLCAR INST OF MEDICINE & SURGERY	DEPT OF NEUROSCIENCE S-171 77	STOCKHOLM		00000		SWE	Cancer Biology Research	002	4	6/24/2016	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$0
2016	2015	UNIVERSITY OF HOUSTON DOWNTOWN	ONE MAIN STREET	HOUSTON	TX	77002	HARRIS	USA	Cancer Biology Research	000	3	4/13/2016	NON-COMPETING CONTINUATION	-$230,077
2016	2015	KAROLINSKA INSTITUTE, RYLCAR INST OF MEDICINE & SURGERY	DEPT OF NEUROSCIENCE S-171 77	STOCKHOLM				SWE	Cancer Biology Research	001	4	4/15/2016	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$230,077
														Subtotal = $0

Issue Date FY: 2015 ( Subtotal = $312,288 )
2015	2015	UNIVERSITY OF HOUSTON DOWNTOWN	ONE MAIN STREET	HOUSTON	TX	77002	HARRIS	USA	Cancer Biology Research	000	3	6/8/2015	NON-COMPETING CONTINUATION	$312,288
														Subtotal = $312,288

Issue Date FY: 2014 ( Subtotal = $302,919 )
2014	2014	UNIVERSITY OF HOUSTON DOWNTOWN	ONE MAIN STREET	HOUSTON	TX	77002	HARRIS	USA	Cancer Biology Research	000	2	5/7/2014	NON-COMPETING CONTINUATION	$302,919
														Subtotal = $302,919

Issue Date FY: 2013 ( Subtotal = $312,201 )
2013	2013	UNIVERSITY OF HOUSTON DOWNTOWN	ONE MAIN STREET	HOUSTON	TX	77002	HARRIS	USA	Cancer Biology Research	000	1	8/1/2013	NEW	$312,201
														Subtotal = $312,201

Grand Total All Awards = $1,375,608

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Elucidating the mechanism of ERbeta in colon carcinogenesis

Award Number: R01CA172437

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2013

PERIOD OF PERFORMANCE END DATE: 03/31/2019

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer